Fedratinib for patients with myelofibrosis

Affiliations

¹ Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands; Department of Hematology-Medical Oncology, Curaçao Medical Center, Willemstad, Curaçao. Electronic address: ruben.vandijck@cmc.cw.
² Department of Hematology-Medical Oncology, Curaçao Medical Center, Willemstad, Curaçao; Curaçao Biomedical and Health Research Institute, Willemstad, Curaçao.
³ Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands.

Comment

Ruben Van Dijck et al. Lancet Haematol. 2025 Apr.

. 2025 Apr;12(4):e240.

doi: 10.1016/S2352-3026(24)00398-3.

¹ Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands; Department of Hematology-Medical Oncology, Curaçao Medical Center, Willemstad, Curaçao. Electronic address: ruben.vandijck@cmc.cw.
² Department of Hematology-Medical Oncology, Curaçao Medical Center, Willemstad, Curaçao; Curaçao Biomedical and Health Research Institute, Willemstad, Curaçao.
³ Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands.

No abstract available

Conflict of interest statement

PtB receives consulting fees from AOP Orphan Pharmaceuticals, Novartis, Sanofi, and Incyte. All other authors declare no competing interests.

Fedratinib for patients with myelofibrosis - Authors' reply.
Harrison CN, Brown P, Kiladjian JJ. Harrison CN, et al. Lancet Haematol. 2025 Apr;12(4):e241-e242. doi: 10.1016/S2352-3026(25)00010-9. Lancet Haematol. 2025. PMID: 40174996 No abstract available.

Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, Palandri F, Benevolo G, Vannucchi AM, Mediavilla C, Iurlo A, Kim I, Rose S, Brown P, Hernandez C, Wang J, Kiladjian JJ. Harrison CN, et al. Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9. Lancet Haematol. 2024. PMID: 39265613 Clinical Trial.